Compare Li Auto Inc (LI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Li Auto Inc trades at $11.29 (market cap $11.27B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Li Auto Inc is far larger — about 2.3× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 102 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LI | TVTX | |
|---|---|---|
Market Cap | $11.27B | $4.88B |
Volume | 3,921,121 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.72 | $67.52 |
52-Week Low | $10.69 | $26.79 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $673.48M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.26, down 1.23% on the day and near its 52-week low, reflecting bearish technical signals and recent delivery declines. The company reported revenue of $112.31B in 2025 with a net income of $1.12B, but profitability metrics like net income margin and ROE remain negative. Recent news highlights challenges in China's EV market, with September 2026 deliveries of 31,817 vehicles showing moderation. Analyst consensus is mixed, with a $15.18 price target suggesting potential upside from current levels.
The outlook for LI is cautious due to intense competition and cash flow pressures, with net cash flow negative $9.0B in 2025. Investment opportunities include new model launches like the Li i9 SUV and global expansion, but risks from market volatility and execution missteps persist. Investors should weigh the company's solid balance sheet against near-term headwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
